Bioniche Life Sciences
Bioniche reports revenues remain flat
Published in Food and Drug Law Weekly, October 27th, 2006
The president & CEO of Bioniche Life Sciences, Inc., Graeme McRae, stated, "Bioniche had an eventful year. The U.S. Food and Drug Administration (FDA) approved our two phase III trial protocols using Urocidin in the treatment of non-muscle invasive bladder cancer. In addition, we were granted fast track status for the refractory protocol, meaning that, when data from the refractory study becomes available, we can expect an expedited review of our Biologics Licensing Application for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
More Articles from Food and Drug Law Weekly
- Acorda Therapeutics
Acorda reports positive results of phase III trial of Fampridine-SR in multiple sclerosis - Advaxis
Advaxis meets with U.S. FDA regarding phase II of Lovaxin C - Alcon
Alcon's Travatan approved by U.S. FDA to treat glaucoma, ocular hypertensive patients - Alexion Pharmaceuticals
Alexion submits market authorization application for Soliris to treat blood disorder - Ascent Healthcare Solutions
Ascent Healthcare receives 510(k) clearance on Medtronic TORQR CS series catheters - Bayer
U.S. FDA Advisory Committee strongly endorses use of Trasylol in CABG surgery patients - More from this issue of Food and Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
